Infection Control and Hospital Epidemiology· 2026Q1
Trends in population attributable risk of Clostridioides difficile infection associated with common outpatient antibiotics in Ontario, Canada, 2017–2024
- 1citations
- Q1SCImago
- 2026year
Short summary
Amoxicillin-clavulanate became the leading contributor to community-associated Clostridioides difficile infection (CA-CDI) in Ontario by 2022, surpassing clindamycin, cephalosporins, and fluoroquinolones.
AI-generated from the title and abstract; the full text is not read.
Key points
- Amoxicillin-clavulanate became the leading contributor to CA-CDI in Ontario by 2022.
- Contributions from clindamycin, cephalosporins, and fluoroquinolones to CA-CDI declined over the study period (2017-2024).
- The findings suggest a need to reassess antimicrobial stewardship targets for CA-CDI prevention.
- The study analyzed data from Ontario, Canada, between 2017 and 2024.
AI-generated from the title and abstract; the full text is not read.
Abstract
Abstract We evaluated changes in population attributable risk of “4C” antibiotics for community-associated Clostridioides difficile infection in Ontario (2017–2024). Contributions from clindamycin, cephalosporins, and fluoroquinolones declined, whereas amoxicillin-clavulanate increased and became the leading contributor by 2022, highlighting a potential emerging target for outpatient antimicrobial stewardship.
The authors' abstract, as published at the source. Infection Control and Hospital Epidemiology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Infectious Diseases
Infectious DiseasesMedicine